Edwin Rock - 19 Jan 2023 Form 4 Insider Report for GLYCOMIMETICS INC (GLYC)

Role
Chief Medical Officer
Signature
/s/ Brian F. Leaf, attorney-in-fact
Issuer symbol
GLYC
Transactions as of
19 Jan 2023
Net transactions value
$0
Form type
4
Filing time
20 Jan 2023, 15:02:04 UTC
Previous filing
27 Dec 2022
Next filing
25 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLYC Employee Stock Option (right to buy) Award $0 +244,800 $0.000000 244,800 19 Jan 2023 Common Stock 244,800 $2.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option will vest on January 19, 2024 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.